Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Genomic Analysis of Patients With Chronic Lymphocytic Leukemia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by Universitaire Ziekenhuizen Leuven.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier:
NCT01346020
First received: April 26, 2011
Last updated: April 29, 2011
Last verified: April 2011

April 26, 2011
April 29, 2011
April 2010
Not Provided
Time to therapy [ Time Frame: baseline to day 1 of therapy ] [ Designated as safety issue: No ]
Time from diagnosis to the start of first line therapy
Same as current
Complete list of historical versions of study NCT01346020 on ClinicalTrials.gov Archive Site
Genetic abnormalities detected by karyotyping, FISH or array-analysis [ Time Frame: 13-102 months ] [ Designated as safety issue: No ]
Detection of any type of genetic abnormality or pattern of abnormalities present at diagnosis or at time of disease progression (e.g. median 41 months after diagnosis, range 13-102 months) by means of karyotyping, fluorescent in situ hybridization or array-analysis.
Same as current
Not Provided
Not Provided
 
Genomic Analysis of Patients With Chronic Lymphocytic Leukemia
Genomic Analysis of Patients With Chronic Lymphocytic Leukemia

This study aims to characterize clonal evolution in chronic lymphocytic leukemia (CLL) using different approaches and to identify a possible association with disease progression, i.e. therapy initiation.

  1. Samples This monocentric study is carried out using representative bioarchived leukemic samples with a diagnosis of CLL, either at diagnosis or at evolution. These bioarchived samples were collected locally at our center during years of diagnostic activity, and were accurately pathologically, cytogenetically and molecularly characterized.
  2. Clinical data The clinical data were retrospectively collected through collaboration with the referring physicians.
  3. Methods Samples will be investigated by means of (1) conventional cytogenetics, (2) fluorescence in situ hybridization (FISH) and (3) SNP-arrays. After analysis of the array data sets, significant results will be validated and in addition, results will be correlated with clinical data.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Patients with chronic lymphocytic leukemia

Chronic Lymphocytic Leukemia
Not Provided
CLL
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
53
Not Provided
Not Provided

Inclusion Criteria:

  • diagnosis of CLL,
  • at least two available stored samples

Exclusion Criteria:

  • at least one inclusion criterium not fulfilled
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT01346020
S53270
Not Provided
dr. Natalie Put, Department of Human Genetics UZLeuven
Universitaire Ziekenhuizen Leuven
Not Provided
Not Provided
Universitaire Ziekenhuizen Leuven
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP